This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Roche Bid Could Alter Pharma's DNA

"In considering Genentech's potential frame of reference for assessing valuation in an acquisition and formulating a counter proposal, we would suggest that a comparable 30x 2009E EPS multiple to large-cap peer Celgene would support a $120 (-per-share) purchase price, that a more typical 35-60% 30-day premium seen in other acquisitions would support a $104-123 purchase price, that a 50-100% premium to our PharmaPipelines NPV of $70 could support a purchase price of $105-140 and that a comparable 10.7x sales multiple afforded MedImmune by AstraZeneca could support a purchase price of $131," the firm said in a note to clients.

"Overall, we believe that $120/share would be a reasonable counter proposal by DNA and that assuming an equitable negotiation would suggest a compromise price of $105/share, in line with a 50% premium to our PharmaPipelines NPV."

The End of an Era

Roche is saying that it will allow Genentech to operate as an independent entity with minimal interference from headquarters in Basel. In fact, Roche's presence in the U.S. will be rebranded under the Genentech name. (A smart move.) Still, will Genentech, under Roche, be given free rein to continue working with its smaller, biotech partners?

What happens to the drug development partnerships with Curis (CRIS - Get Report), Immunogen (IMGN - Get Report) and Seattle Genetics (SGEN - Get Report), for example?

If Roche is true to its word, Genentech will be free to pursue its early-stage drug development with the same freedom it has today, which bodes well for the existing partnerships, hopefully.

Genentech makes up 39% of the assets in the Biotech HOLDRs (BBH) exchange-traded fund. What happens when Genentech disappears as a separate, publicly traded company.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $244.00 -0.45%
CELG $100.23 0.64%
CRIS $1.42 7.60%
GILD $89.52 2.50%
IMGN $7.03 -0.85%


Chart of I:DJI
DOW 15,888.33 +228.15 1.46%
S&P 500 1,853.17 +24.09 1.32%
NASDAQ 4,307.7790 +40.9420 0.96%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs